# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-089246
Filing Date
2024-08-01
Accepted
2024-08-01 16:05:23
Documents
50
Period of Report
2024-06-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | abio-20240630.htm iXBRL | 10-Q | 1337108
2 | EX-31.1 | abio-ex31_1.htm | EX-31.1 | 11455
3 | EX-31.2 | abio-ex31_2.htm | EX-31.2 | 11323
4 | EX-32.1 | abio-ex32_1.htm | EX-32.1 | 13465
| Complete submission text file | 0000950170-24-089246.txt |  | 4577607

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
5 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | abio-20240630.xsd | EX-101.SCH | 721739
52 | EXTRACTED XBRL INSTANCE DOCUMENT | abio-20240630_htm.xml | XML | 488701

Mailing Address 10170 CHURCH RANCH WAY SUITE 100 WESTMINSTER CO 80021
Business Address 10170 CHURCH RANCH WAY SUITE 100 WESTMINSTER CO 80021 7209402200
ARCA biopharma, Inc. (Filer) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-22873 | Film No.: 241166534
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)